Summary
Eticyclidine (PCE, CI-400) is a dissociative anesthetic substance renowned for its hallucinogenic properties. It shares similarities in effects with phencyclidine but is marginally more potent. Developed by Parke-Davis during the 1970s, PCE underwent anesthetic evaluation under the codename CI-400. However, research into PCE was discontinued following the emergence of ketamine, a comparable drug with more favorable characteristics. PCE, though slightly more potent than PCP with similar effects[medical citation needed], faced challenges due to its unpalatable taste and the tendency to induce nausea, resulting in limited popularity among users. Owing to its analogous effects to PCP, PCE was classified as a Schedule 1 controlled substance in the 1970s, even though its abuse was brief in the 1970s and 1980s, and it is now relatively obscure.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 2201-15-2 |
|---|---|
| PubChem CID | 16622 |
| ChemSpider | 15759 |
| UNII | O8I1LL6A89 |
| ChEMBL | ChEMBL279924 |
| CompTox Dashboard (EPA) | DTXSID2062248 |
| Chemical and physical data | |
| Formula | C14H21N |
| Molar mass | 203.329 g·mol−1 |
FAQ
1. What is Eticyclidine (PCE)?
Eticyclidine, often referred to as PCE, is a dissociative anesthetic drug known for its hallucinogenic effects. It shares similarities with phencyclidine (PCP) but is slightly more potent.
2. How is PCE used?
PCE can be used through various methods, such as ingestion or inhalation. However, it’s essential to note that PCE is a controlled substance in many regions and should not be used without considering legal implications and potential health risks.
3. What are the effects of PCE?
PCE’s effects include dissociation from reality, altered sensory perception, and hallucinations. Users may experience experiences that are both desired and potentially unpleasant or uncomfortable.
4. Why was PCE developed, and what is its history?
PCE was initially developed by Parke-Davis in the 1970s and evaluated for its anesthetic potential under the code name CI-400. However, research into PCE was discontinued after the introduction of ketamine, a similar drug with more favorable properties. PCE is slightly more potent than PCP and shares similar effects, but its unpalatable taste and tendency to induce nausea made it less popular among users.
5. Is PCE legal for use?
PCE is classified as a controlled substance in many jurisdictions due to its potential for abuse and associated risks. It is essential to understand and comply with local laws and regulations when considering the use of PCE.
6. Are there potential risks or side effects associated with PCE?
Using PCE can lead to a range of side effects, including disorientation, anxiety, paranoia, and nausea. Prolonged or excessive use may have a long-term impact on mental health. Responsible and cautious use is advised.
7. Is PCE addictive?
There is evidence to suggest that PCE can be habit-forming, potentially leading to dependence in some individuals. Using it with moderation and understanding the risks is crucial.
8. Is PCE used for medical purposes?
PCE is not approved for medical use and is primarily associated with recreational or research purposes. Self-medicating with this substance is discouraged due to a lack of scientific evidence supporting its therapeutic use.
9. Where can I find more information about PCE?
For additional information about Eticyclidine (PCE), its effects, legal status, and potential risks, consider consulting with a healthcare professional or referring to authoritative sources such as scientific literature, government health agencies, and reputable drug education websites.
References
- Anvisa, in a resolution dated July 24, 2023, issued Collegiate Board Resolution No. 804, listing substances under special control, including narcotic, psychotropic, precursor, and other substances, in accordance with Brazilian regulations.
- In March 1960, Levy, Cameron, and Aitken conducted observations on two psychotomimetic drugs derived from piperidine—CI 395 (sernyl) and CI 400. Their research shed light on the effects and properties of these compounds.
- Kalir, Edery, Pelah, Balderman, and Porath explored the synthesis and pharmacological activity of 1-phenylcycloalkylamine derivatives in May 1969. Their study delved into the chemical and pharmacological aspects of these compounds, contributing to our understanding of their properties.